Skip to main navigation Skip to search Skip to main content

Prediction Rules for Ruling Out Endocarditis in Patients With Staphylococcus aureus Bacteremia

  • Thomas W van der Vaart
  • , Jan M Prins
  • , Robin Soetekouw
  • , Gitte van Twillert
  • , Jan Veenstra
  • , Bjorn L Herpers
  • , Wouter Rozemeijer
  • , Rogier R Jansen
  • , Marc J M Bonten
  • , Jan T M van der Meer
  • Department of Internal Medicine and Geriatric Medicine
  • Department of Medical Microbiology
  • Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht.
  • Department of Sciences, Amsterdam University College, VU Amsterdam/University of Amsterdam, 1012 WX, Amsterdam, The Netherlands
  • Utrecht University
  • University of Amsterdam
  • Spaarne Gasthuis
  • Noordwest Ziekenhuisgroep
  • Onze Lieve Vrouwe Gasthuis

Research output: Contribution to journalArticleAcademicpeer-review

75 Downloads (Pure)

Abstract

BACKGROUND: Staphylococcus aureus bacteremia (SAB) is in 10% to 20% of cases complicated by infective endocarditis. Clinical prediction scores may select patients with SAB at highest risk for endocarditis, improving the diagnostic process of endocarditis. We compared the accuracy of the Prediction Of Staphylococcus aureus Infective endocarditiseTime to positivity, Iv drug use, Vascular phenomena, preExisting heart condition (POSITIVE), Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT), and VIRSTA scores for classifying the likelihood of endocarditis in patients with SAB. METHODS: Between August 2017 and September 2019, we enrolled consecutive adult patients with SAB in a prospective cohort study in 7 hospitals in the Netherlands. Using the modified Duke Criteria for definite endocarditis as reference standard, sensitivity, specificity, negative predictive (NPV), and positive predictive values were determined for the POSITIVE, PREDICT, and VIRSTA scores. An NPV of at least 98% was considered safe for excluding endocarditis. RESULTS: Of 477 SAB patients enrolled, 33% had community-acquired SAB, 8% had a prosthetic valve, and 11% a cardiac implantable electronic device. Echocardiography was performed in 87% of patients, and 42% received transesophageal echocardiography (TEE). Eighty-seven (18.2%) had definite endocarditis. Sensitivity was 77.6% (65.8%-86.9%), 85.1% (75.8%-91.8%), and 98.9% (95.7%-100%) for the POSITIVE (n = 362), PREDICT, and VIRSTA scores, respectively. NPVs were 92.5% (87.9%-95.8%), 94.5% (90.7%-97.0%), and 99.3% (94.9%-100%). For the POSITIVE, PREDICT, and VIRSTA scores, 44.5%, 50.7%, and 70.9% of patients with SAB, respectively, were classified as at high risk for endocarditis. CONCLUSIONS: Only the VIRSTA score had an NPV of at least 98%, but at the expense of a high number of patients classified as high risk and thus requiring TEE. CLINICAL TRIALS REGISTRATION: Netherlands Trial Register code 6669.
Original languageEnglish
Pages (from-to)1442-1449
Number of pages8
JournalClinical infectious diseases
Volume74
Issue number8
Early online date16 Jul 2021
DOIs
Publication statusPublished - 15 Apr 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Staphylococcus aureus bacteremia
  • echocardiography
  • endocarditis
  • risk stratification

Fingerprint

Dive into the research topics of 'Prediction Rules for Ruling Out Endocarditis in Patients With Staphylococcus aureus Bacteremia'. Together they form a unique fingerprint.

Cite this